Arcellx

Arcellx Financing Cash Flow

Delisted

The Net Financing Cash Flow of Arcellx (ACLX) as of Nov 21, 2026 is 98.53 M USD. In the previous year, Net Financing Cash Flow was -24.09 M USD — a change of -509.08% (higher).

Financing Cash Flow

98.53 MUSD

YoY

-509.08%

Last updated:

Net Financing Cash Flow of Arcellx is 2025 98.53 M USD. Net Financing Cash Flow of Arcellx was 2024 -24.09 M USD. It decreases by -509.08% higher compared to the previous year.

The Arcellx Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
12.48 M USD
Jan 1, 2019
42.65 M USD
Jan 1, 2020
41.66 M USD
Jan 1, 2021
118.45 M USD
Jan 1, 2022
252.63 M USD
Jan 1, 2023
279.16 M USD
Jan 1, 2024
-24.09 M USD
Jan 1, 2025
98.53 M USD
The Arcellx Financing Cash Flow history
YEARFinancing Cash FlowYoY
98.53 MUSD-509.08%
-24.09 MUSD-108.63%
279.16 MUSD+10.50%
252.63 MUSD+113.27%
118.45 MUSD+184.36%
41.66 MUSD-2.34%
42.65 MUSD+241.79%
12.48 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

Net Financing Cash Flow of Arcellx is 98.53 M USD in 2025.

Net Financing Cash Flow of Arcellx changed from -24.09 M USD to 98.53 M USD, representing a -509.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Arcellx since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Arcellx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Arcellx

All Key Metrics — Arcellx